Inhibition of RIP2/RIck/CARDIAK activity by pyridinyl imidazole inhibitors of p38 MAPK.
Pyridinyl imidazole inhibitors of p38 mitogen-activated protein kinase (MAPK) have been used extensively in vitro and in vivo to investigate the role of p38 in physiological processes. As with other pharmacological inhibitors, non-specific targets of the p38 inhibitors have been reported. We have found that the protein kinase receptor interacting protein-2 (RIP2) is another target for the family of p38 inhibitors. The autophosphorylation of RIP2 was inhibited in vitro by the p38 inhibitors SB220025, SB203580 and PD169316 at concentrations comparable to those used to inhibit p38. We also identified two new in vitro substrates for RIP2, myelin basic protein and histone H3 with apparent Km values of 2.1 microM and 0.65 microM, respectively. The ability of RIP2 to phosphorylate these two substrates was sensitive to the p38 inhibitors as well. As was shown for p38alpha, a conserved threonine in the kinase domain of RIP2 is required for sensitivity to the inhibitors, indicating that the mechanism of inhibition of RIP2 is similar to that of p38. These results demonstrate that the pyridinyl imidazole inhibitors block RIP2 as well as p38 kinase activity.
Argast
Gretchen M
GM
Department of Chemistry and Biochemistry, University of Colorado at Boulder, Boulder, CO, USA.
Fausto
Nelson
N
Campbell
Jean S
JS
D002460:Cell Line; D004791:Enzyme Inhibitors / Q000494:pharmacology*; D006801:Humans; D007093:Imidazoles / Q000494:pharmacology*; D010766:Phosphorylation / Q000187:drug effects; D017346:Protein Serine-Threonine Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism; D017434:Protein Structure, Tertiary / Q000502:physiology; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2; D013379:Substrate Specificity; D048051:p38 Mitogen-Activated Protein Kinases / Q000037:antagonists & inhibitors* / Q000378:metabolism
D004791:Enzyme Inhibitors; D007093:Imidazoles; D017346:Protein Serine-Threonine Kinases; C506253:RIPK2 protein, human; D053475:Receptor-Interacting Protein Serine-Threonine Kinase 2; D048051:p38 Mitogen-Activated Protein Kinases
J Biol Chem. 2000 Mar 10;275(10 ):7395-402
10702313
FEBS Lett. 1999 Feb 5;444(1):71-4
10037150
EMBO J. 1996 Apr 15;15(8):1914-23
8617238
Proc Natl Acad Sci U S A. 1994 Jan 18;91(2):674-8
7904757
J Biol Chem. 1998 Jul 3;273(27):16968-75
9642260
J Biol Chem. 2002 Aug 9;277(32):28364-7
12077112
FEBS Lett. 1999 May 21;451(2):191-6
10371163
Biochemistry. 1998 Nov 24;37(47):16573-81
9843424
Biochemistry. 1997 Aug 26;36(34):10422-7
9265622
Oncogene. 1999 Mar 25;18(12 ):2047-54
10321729
EMBO Rep. 2002 Dec;3(12):1201-8
12446564
Biochem J. 2000 Oct 1;351(Pt 1):95-105
10998351
J Biol Chem. 1999 Nov 19;274(47):33684-90
10559258
Chem Biol. 1997 Jun;4(6):423-31
9224565
Cell. 2000 Sep 29;103(1):99-111
11051551
Structure. 1998 Sep 15;6(9):1117-28
9753691
Mol Cell Biol. 2003 Jan;23 (2):425-36
12509443
Proc Natl Acad Sci U S A. 2003 Dec 23;100(26):15434-9
14668439
J Biol Chem. 1998 May 15;273(20):12296-300
9575181
J Clin Immunol. 2001 Jul;21(4):253-7
11506194
FEBS Lett. 1998 Apr 10;426(1):93-6
9598985
Nature. 1994 Dec 22-29;372(6508):739-46
7997261
J Biol Chem. 1998 Jun 19;273(25):15605-10
9624152
Nature. 2002 Mar 14;416(6877):194-9
11894098
Chem Biol. 1998 Jun;5(6):321-8
9653550
J Biol Chem. 2003 Aug 22;278(34):31941-9
12775719
Nature. 2002 Mar 14;416(6877):190-4
11894097
Curr Biol. 1998 Jul 16;8(15):885-8
9705938
J Biol Chem. 1998 Oct 30;273(44):28766-72
9786874
J Biol Chem. 1997 May 2;272(18):12116-21
9115281
J Pharmacol Exp Ther. 1998 Feb;284(2):687-92
9454815
Bioorg Med Chem. 1997 Jan;5(1):49-64
9043657